Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease

2024-9-10

The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

2024-7-29

Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

2024-7-29

Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview

2024-7-29

Usefulness of dalbavancin in early discharge and non-hospitalization. It’s time to throw your heart over the obstacle?

2024-7-29

Clinical pharmacy and telemedicine: an opportunity to improve epilepsy management

2024-7-22

Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel

2024-7-15

Exploring the administrative burden faced by hematologists: a comprehensive study in Italy

2024-7-3

Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases

2024-7-3

Early access programs for medicines: a reform proposal for the Italian National Health Service

2024-6-17

Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)

2024-6-11

How effective are prescriptive governance tools? Results from the application of AIFA notes

2024-6-10

Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders

2024-5-22

The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service

2024-5-21

Patient-reported outcomes in epilepsy: a case study exploring their usage and impact

2024-5-3

Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy

2024-5-2

Regional administrative data and their role in planning, programming and controlling at regional level

2024-4-25

Heart failure and economic impact: an analysis in real clinical practice in Italy

2024-4-22

The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain

2024-4-5

The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example

2024-4-3

Regional Formularies in Italy: current state and future perspectives

2024-3-8

Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

2024-3-7

HTA regulation: how is Italy moving?

2024-3-5

Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

2024-2-16

Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis

2024-1-23

Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)

2024-1-15

The future of drugs distribution in the National Health System

2024-1-15

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

2024-1-9

New organizational and governance strategies in the management of epilepsy in Italy

2023-12-30

The role of the hospital and community pharmacist in continuity of care for the management of epilepsy

2023-12-30

Models of care and relevance of territorial management in assisting Persons with Epilepsy

2023-12-30

Orphan drugs in Italy: availability and time-to-access at regional level

2023-12-28

Personalized support programs with innovative digital tools to manage and monitor patients suffering from epilepsy: EpiOnApp case study

2023-12-27

Time to market access in Italy: duration of the P&R process for rare disease drugs

2023-10-31

Unmet need: definitions, literature evidence and implications for HTA

2023-10-2

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

2023-9-28

Good practices for the development of budget impact models at regional level

2023-6-26

COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

2023-5-31

Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members

2023-5-2

Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

2023-4-11

Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

2023-4-11

The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy

2023-2-9

Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis

2023-2-6

Drugs territorialization in the era of PNRR: perspectives, opportunities and considerations from a panel of experts

2022-12-5

Disability weights for castration-resistant prostate cancer: an empirical investigation

2022-11-14

Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

2022-11-10

Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

2022-10-18

Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

2022-10-10

Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

2022-10-5

Value generated by the multiplier effect of investments by the pharmaceutical industry in Italy: proposals to promote competitiveness and attractiveness

2022-10-5